Abstract 270P
Background
The companion diagnostic for olaparib against prostate cancer, which aims to detect BRCA1 or BRCA2 gene (BRCA1/2) variants, was investigated in December 2020 in Japan. There have been no reports on germline BRCA1/2 variants in actual clinical practice. Here, we evaluate germline BRCA1/2 variants and their relationship to the clinical characteristics and outcomes in prostate cancer.
Methods
Between June 2021 and June 2023, 92 patients with prostate cancer were examined using germline BRCA1/2 testing. Further, the associations between pathogenic variants and clinical outcomes were assessed.
Results
Of the 92 patients referred from the Iwate prefecture in Japan for genetic testing, six patients (6.5%) carried germline pathogenic variants; BRCA2 was the most frequent (n=5, 5.4%), followed by BRCA1 (n=1, 1.1%). Among the six variants in BRCA2, p.Ala338Valfs*11 was identified for the first time. Patients with the BRCA1/2 variant exhibited poor outcomes for overall survival from castration-resistant prostate cancer (CRPC), first-line androgen receptor-axis-targeted therapy (ARAT) for CRPC, and taxane chemotherapy (hazard ratio [HR] 4.77, 95% CI: 1.00 to 22.6, P=0.049; HR=5.27, 95% CI: 1.77 to 15.7, P=0.0028; and HR=7.47, 95% CI: 1.49 to 37.4, P=0.014, respectively).
Conclusions
In this study, patients with prostate cancer possessing germline variants of BRCA1/2 genes exhibited poor clinical response to ARAT for CRPC and taxane chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract